Earnings quality
Compare earnings and operating cash flow for earnings quality.
Abbott Laboratories
Ticker ABT · 🇺🇸 United States · Consolidated US GAAP · amounts in dollars
Filed 2026-02-20 · Period end 2025-12-31
Takeaway
Worth trackingSales and operating profit both moved in a healthier direction.
operating margin is 18.2%; equity ratio is 60.1%.
Sales and operating profit moved together — keep watching margins and whether the trend persists next period.
ActionWorth tracking
OP margin18.2%
Equity ratio60.1%
Last price—
Trailing P/E—
Look at next
- Compare operating cash flow to reported profit across the last two years.
- Open English IR for management commentary on outlook and capital allocation.
- Overlay peers on Compare before judging relative momentum.
About the company
ABBOTT LABORATORIES is a US-listed company with consolidated financial statements filed on SEC EDGAR.
Compare trends
Tel 2246676100 · As of filing date 2026-02-20
Financial statements
Income statement
| Account | FY2024 (ended Dec 31, 2024) | FY2025 (ended Dec 31, 2025) |
|---|---|---|
| Revenue | $42.0B | $44.3B |
| Cost of sales* | $37.7B | $39.9B |
| Gross profit | $4.2B | $4.4B |
| Operating profit | $6.8B | $8.1B |
| Income tax | -$6.4B | $1.9B |
| Net income | $13.4B | $6.5B |
| Basic EPS | 7.67 | 3.73 |
Balance sheet
| Account | FY2024 (ended Dec 31, 2024) | FY2025 (ended Dec 31, 2025) |
|---|---|---|
| Cash & equivalents | $7.6B | $8.5B |
| Current assets | $23.7B | $26.0B |
| Non-current assets* | $57.8B | $60.7B |
| Total assets | $81.4B | $86.7B |
| Current liabilities | $14.2B | $16.5B |
| Non-current liabilities* | — | — |
| Total liabilities | — | — |
| Stockholders’ equity | $47.7B | $52.1B |
Cash flow statement
| Account | FY2024 (ended Dec 31, 2024) | FY2025 (ended Dec 31, 2025) |
|---|---|---|
| Operating cash flow | $8.6B | $9.6B |
| Investing cash flow | -$2.3B | -$2.4B |
| Financing cash flow | -$5.4B | -$6.3B |
| Cash at end of period | $7.6B | $8.5B |
Five-year trends
Key metrics
| Metric | Trend | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B | |
| Operating profit | $8.4B | $8.4B | $6.5B | $6.8B | $8.1B | |
| Net income | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B | |
| Total assets | $75.2B | $74.4B | $73.2B | $81.4B | $86.7B | |
| Cash & equivalents | $9.8B | $9.9B | $6.9B | $7.6B | $8.5B | |
| Stockholders’ equity | $35.8B | $36.7B | $38.6B | $47.7B | $52.1B |
How we read these numbers
From the notes
No material one-offs extracted from this filing.
Constructive
Sales and operating profit both moved in a healthier direction.
On the income statement, revenue moved from $42.0B to $44.3B (▲ +5.7%). Operating profit went from $6.8B to $8.1B (▲ +18.0%).
Operating cash flow was $9.6B (prior $8.6B), with cash on the balance sheet at $8.5B versus $7.6B.
Liquidity & leverage
Cash moved from $7.6B to $8.5B; current liabilities $16.5B.
Capital buffer
Stockholders’ equity moved from $47.7B to $52.1B.
Was this page helpful?
Source: SEC EDGAR 0001628280-26-010185
(ABBOTT LABORATORIES), period end 2025-12-31.